Chengdu Brilliant Pharmaceutical Co., Ltd. (referred to as "Brilliant Pharmaceuticals") is a high-and-new technology enterprise that engages in pharmaceutical innovation and high-quality medicine research, development, production and sales. It has been committed to four major research directions of characteristic API, high-end generic drugs, innovative drugs and novel drug delivery system, thus realizing comprehensive pharmaceutical industry chain layout from intermediates (INT), APIs and Finished Drug Formulations (FDFs), which covers Chemical Drugs (including Radiopharmaceuticals), Biological Drugs and Chinese Patent Medicine.

Adhering to the mission of "Let everyone have health, make life more energetic", Brilliant Pharmaceuticals continues to contribute to the development of China's pharmaceutical industry with "Brilliant Innovation" and "Brilliant Efficiency".

With innovation as the engine, Brilliant Pharmaceuticals is working diligently to protect human health. Relying on the National Enterprise Technology Center, the company effectively integrates the world's excellent R&D resources, constantly overcome the technical problems of high-end generic drugs, and accelerate the development of innovative drug R&D and industrialization. The company has established innovation platforms covering fields of Generic Drugs & Modified New Drugs, Biomacromolecule Innovative Drugs, Small Molecule Innovative Drugs, Cell and Gene Therapy, Radiopharmaceuticals, and proceeded with innovation discovery in Chinese Patent Medicine. At present, the company is researching more than 300 projects.

Consolidate the industrialization ability to help build a modern pharmaceutical industry system. The company owns more than ten production bases in Chengdu, Guang'an, Haikou, Shanghai, Hangzhou, Hong Kong, including 7 FDF production bases, one API production base and one INT production base, as well as some international preparation production bases and new API production bases under construction. The company insists on high quality development, which builds a comprehensive production quality management system in line with international standards. Production bases that have been put into operation have passed new GMP certification in China, while some of which have passed the GMP of EU, Japan and South Korea. Practicing green production, the company's API production base and comprehensive preparation production base have been recognized as provincial or national green factory successively.

The company provides multi-field service to human health with diversified product system. The company has wide coverage and diversified product system, which has more than 200 kinds of preparation products sold on market, including drugs for tumor and immunity, respiration, blood, obstetrics and gynecology, infection, contrast medium, cardio cerebrovascular, muscular and skeletal systems, mental and nervous systems. Brilliant Pharmaceuticals' products have been sold across the country and promoted globally with the diversified marketing strategies and through two major marketing systems focusing on API and FDF. Some API applications have been exported to more than 20 countries and regions, including the United States, the European Union, Japan, South Korea, Russia and Africa.

With solid comprehensive strength, Brilliant Pharmaceuticals has been ranked as Top 100 of Pharmaceutical Industry in China since 2013 (Ranked the 46^th in 2024), and won the National Intellectual Property Advantage Enterprise, Sichuan Excellent Private Enterprise, Sichuan Top 100 Private Enterprises and other awards. The company was identified as The First Batch of Centralized Production Base Construction Unit of Small-variety Drugs (Drugs in Short Supply) of China and National Postdoctoral Scientific Research Workstation.

（Last updated Dec, 2024）